Information de reference pour ce titreAccession Number: | 00001716-200310080-00002.
|
Author: | KULIG, M. *; LEODOLTER, A. +; VIETH, M. +; SCHULTE, E. *; JASPERSEN, D. ++; LABENZ, J. [S]; LIND, T. [P]; MEYER-SABELLEK, W. [P]; MALFERTHEINER, P. +; STOLTE, M. **; WILLICH, S. N. *
|
Institution: | (*)Institute of Social Medicine, Epidemiology, and Health Economics, Charite University Medical Center, Berlin, Germany +Department of Gastroenterology, Otto-von-Guericke University, Magdeburg, Germany ++Klinikum Fulda, Fulda, Germany [S]Ev. Jung-Stilling-Krankenhaus, Siegen, Germany [P]AstraZeneca, Wedel, Germany and M[latin small letter o with ring above]lndal, Sweden (**)Institute of Pathology, Klinikum Bayreuth, Bayreuth, Germany
|
Title: | |
Source: | Alimentary Pharmacology & Therapeutics. 18(8):767-776, October 2003.
|
Abstract: | Aims: To determine the impact of gastro-oesophageal reflux disease (GERD) on the quality of life, to assess changes in the quality of life during treatment with esomeprazole and to define factors that can predict these changes.
Methods: Patients with GERD (n = 6215) were included in a prospective cohort study (ProGERD). All patients underwent endoscopy and received esomeprazole. At baseline and after 2 weeks of treatment, symptoms and quality of life were assessed. Factors that influenced changes in the quality of life were determined by multiple regression analyses.
Results: At baseline, the quality of life in GERD patients was lower than that in the general population, and was similar to that in patients after acute coronary events. No differences in symptoms or quality of life were observed between the subgroups of patients with non-erosive GERD, erosive GERD and Barrett's oesophagus. After treatment with esomeprazole, the symptoms and quality of life were improved in all subscales within 2 weeks (P < 0.001). The mean score of the disease-specific quality of life instrument (Quality of Life in Reflux and Dyspepsia Patients) increased from 4.6 to 6.2 points, representing a highly relevant clinical improvement. The generic quality of life (SF-36) reached levels similar to those in the general population, but, again, no difference was found between the three different subgroups of GERD patients. The main factors associated with an improvement in the quality of life after treatment were symptom relief, severe erosive reflux disease, absence of extra-oesophageal disorders, avoidance of non-steroidal anti-inflammatory drug intake and positive Helicobacter pylori status.
Conclusions: GERD causes a significant impairment in the quality of life that can be attenuated or normalized within a time period as short as 2 weeks by treatment with esomeprazole. These findings were similar across the whole GERD patient spectrum.
(C) 2003 Blackwell Science Ltd.
|
References: | 1 Wiklund I, Butler-Wheelhouse P. Psychosocial factors and their role in symptomatic gastroesophageal reflux disease and functional dyspepsia. Scand J Gastroenterol Suppl 1996; 220: 94-100.
2 Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 24-9.
3 Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976; 21(11): 953-6.
4 Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - The Genval Workshop Report. Gut 1999; 44(Suppl. 2): 1-16.
5 Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340(11): 825-31.
6 Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. Br Med J 2000; 321(7271): 1252-5.
7 Gudlaugsdottir S, van Blankenstein M, Dees J, et al. A majority of patients with Barrett's oesophagus are unlikely to benefit from endoscopic cancer surveillance. Eur J Gastroenterol Hepatol 2001; 13(6): 639-45.
8 Eckardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. Am J Med 2001; 111(1): 33-7.
9 Frank L, Kleinman L, Ganoczy D, McQuaid K, Sloan S. Upper gastrointestinal symptoms in North America: prevalence and relationship to health care utilization and quality of life. Dig Dis Sci 2000; 45: 809-18.
10 Henke CJ, Levin TR, Henning JM, Potter LP. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization. Am J Gastroenterol 2000; 95: 788-92.
11 Graham DY, Smith JL, Patterson DJ. Why do apparently healthy people use antacid tablets? Am J Gastroenterol 1983; 78(5): 257-60.
12 Dimenas E, Glise H, Hallerback B, et al. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993; 28(8): 681-7.
13 Tebaldi M, Heading RC. Quality of life assessment in reflux disease. Eur J Gastroenterol Hepatol 1998; 10(6): 451-4.
14 Wiklund I, Bardhan KD, Muller-Lissner S, et al. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group. Ital J Gastroenterol Hepatol 1998; 30(1): 19-27.
15 Revicki DA, Wood M, Maton PN, et al. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998; 104(3): 252-8.
16 Revicki DA, Crawley JA, Zodet MW, et al. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13(12): 1621-30.
17 Havelund T, Lind T, Wiklund I, et al. Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 1999; 94(7): 1782-9.
18 Eloubeidi MA, Provenzale D. Health-related quality of life and severity of symptoms in patients with Barrett's esophagus and gastroesophageal reflux disease patients without Barrett's esophagus. Am J Gastroenterol 2000; 95(8): 1881-7.
19 Revicki DA, Sorensen S, Maton PN, et al. Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease. Dig Dis 1998; 16(5): 284-91.
20 Kulig M, Leodolter A, Nocon M, et al. Patients with gastroesophageal reflux disease - design and first epidemiologic results of the ProGERD study. J Clin Epidemiol 2003 in press.
21 Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45(2): 172-80.
22 Shaw MJ, Talley NJ, Beebe TJ, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001; 96: 52-7.
23 Wiklund IK, Junghard O, Grace E, et al. Quality of Life in Reflux and Dyspepsia Patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl 1998; 583: 41-9.
24 Talley NJ, Fullerton S, Junghard O, et al. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol 2001; 96(7): 1998-2004.
25 Ware JEJ, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30(6): 473-83.
26 Ware JE, Snow KK, Kosinski M, et al. SF-36 Health Survey. Manual and Interpretation Guide. Boston, MA: New England Medical Center, The Health Institute, 1993.
27 Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Summary Scales: A User's Manual. Boston, MA: New England Medical Center, The Health Institute, 1994.
28 Bullinger M. German translation and psychometric testing of the SF-36 Health Survey: preliminary results from the IQOLA Project. Int Quality Life Assessment Soc Sci Med 1995; 41: 1359-66.
29 Guyatt GH, Juniper EF, Walter SD, et al. Interpreting treatment effects in randomised trials. Br Med J 1998; 316(7132): 690-3.
30 Lydick E, Epstein RS. Interpretation of quality of life changes. Qual Life Res 1993; 2: 221-6.
31 Kazis L, Anderson J, Meenan R. Effect sizes for interpreting changes in health status. Med Care 1989; 27: 178-89.
32 Cohen J. Statistical Power Analysis for the Behavioural Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
33 Bullinger M, Kirchberger I. Der SF-36 Fragebogen zum Gesundheitszustand. Handbuch fur die Deutschsprachige Fragebogenversion. Gottingen, Bern, Toronto, Seattle: Hogrefe Verlag fur Psychologie, 1998.
34 Ware JE, Gandek B, Kosinski M, et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries. J Clin Epidemiol 1998; 51: 1167-70.
35 Hemingway H, Stafford M, Stansfeld S, et al. Is the SF-36 a valid measure of change in population health? Results from the Whitehall II Study. Br Med J 1997; 513: 1273-9.
36 Willich SN, Muller-Nordhorn J, Kulig M, et al. Cardiac risk factors, medication, and recurrent clinical events after acute coronary disease - a prospective cohort study. Eur Heart J 2001; 22: 307-13.
37 Muller-Nordhorn J, Kulig M, Binting S, et al. for the PIN Study Group. Change in quality of life in the year following cardiac rehabilitation - is it clinically relevant and what are its predictors? Qual Life Res 2003 in press.
38 Velanovich V, Karmy-Jones R. Measuring gastroesophageal reflux disease: relationship between the health-related quality of life and physiologic parameters. Am Surg 1998; 64: 649-53.
39 Farup C, Kleinman L, Sloan S, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001; 161: 45-52.
|
Language: | English.
|
Document Type: | Original Articles.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0269-2813
|
NLM Journal Code: | a5d, 8707234
|
Annotation(s) | |
|
|